Epinephrine and Cortisol in Depression

Depression Clinical Trial

Official title:

The Effects of Epinephrine and Cortisol on Emotion in Depression

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04148261
• Other study ID #: 53325
• Status: Withdrawn
• Phase: Early Phase 1
• Start date: December 2020
• Est. completion date: December 2022

Study information

• Verified date: September 2021
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study investigates the effects of two hormones called epinephrine and cortisol on how the brain processes emotional material using functional MRI to measure brain activity. The study hopes to learn how epinephrine and cortisol affect the brain differently in depressed and non-depressed individuals.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2022
• Est. primary completion date: December 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 55 Years

Eligibility

Inclusion Criteria:

• Weight of less than 280 pounds

• HAM-D Score of greater than 7 for depression participants

Exclusion Criteria:

• Psychotropic medications

• Recent surgery

• Endocrine disorders

• Liver disease

• Kidney disease

• Thyroid disorder

• History of malaria

• Tuberculosis

• Osteoporosis

• Glaucoma or cataracts

• Chronic expressed infections (herpes, HIV, etc)

• History of congestive heart failure

• History of recurring seizures

• Stomach ulcers

• Comorbid psychosis

• Current use of illicit drugs

• Diabetes

• Any cardiovascular disease (angina, hypovolemia, coronary artery disease, low/high blood pressure, etc)

• Any pulmonary disease

• Any cerebrovascular disease

• Sulfate hypersensitivity

• Glaucoma

• Infection

• Pregnancy

• Parkinson's Disease

• Panic Disorder

• Over 280 pounds in weight

• In-dwelling ferrous metals

• Left handed

• Abnormal hearing

• Claustrophobic

• Head injury with loss of consciousness

• Active suicidal ideation

Related Conditions & MeSH terms

• Depression
• Depressive Disorder

Intervention

Drug:
• Hydrocortisone Acetate (CORT)
Participants will receive a single dose of hydrocortisone at a dosage of 0.65 mg/kg
• Epinephrine Sulfate (EPI)
Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min
• Placebo (PLB)
Participants will receive a placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sadness-induced subgenual cingulate activity as measured by functional magnetic resonance imaging		2 hours